University of Alabama Birmingham
Welcome,         Profile    Billing    Logout  
 124 Trials 
107 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jansen, Jan
MOBI-1, NCT04893837: Non-Invasive Monitoring of Traumatic Brain Injury Progression Using the Infrascanner

Recruiting
N/A
440
US
Standard care plus infrascans
University of Alabama at Birmingham, United States Department of Defense, InfraScan, Inc.
Brain Injuries, Traumatic
06/25
06/25
III, Charles F Reynolds
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
07/24
11/25
Shelton, Richard C
NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Terminated
3
83
Europe, Canada, Japan, US
SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo
Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc.
Depressive Episodes, Bipolar I Depression
10/23
10/23
NCT05729373: A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

Recruiting
2/3
434
Europe, Japan, US
SEP-363856, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
02/26
02/26
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression

Completed
2
197
Canada, US
Liafensine, Placebo
Denovo Biopharma LLC
Treatment Resistant Depression
02/24
03/24
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Locke, Jayme
NCT05340426: Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

Withdrawn
1
20
US
UKidney, Porcine Kidney, Xenotransplant
University of Alabama at Birmingham, United Therapeutics, Lung Biotechnology PBC
Kidney Failure, Chronic
06/28
06/29
Saag, Kenneth G
NCT04177940 / 2020-004903-15: Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study

Active, not recruiting
4
45
US
DMAB Discontinuation and Switching
University of Alabama at Birmingham, Maastricht University, Vrije Universiteit Brussel, Amgen
Osteoporosis
08/25
08/25
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
Wang, Henry
ELSA-2, NCT05128955: Embolization of the Splenic Artery After Trauma

Recruiting
N/A
250
US
Splenic artery embolization with vascular embolic coils or plugs
Andrew J. Gunn, Penumbra Inc.
High-grade Splenic Injuries
04/25
04/25
Amara, Amy
NCT06219629: Parkinson's Disease Progression Study

Recruiting
N/A
70
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
08/25
09/25
Roberson, Erik
DIAN-TU, NCT06384573: Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Recruiting
3
65
Europe, US, RoW
lecanemab, BAN2401
Washington University School of Medicine, Alzheimer's Association, Eisai Inc.
Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
11/29
11/29
DIAN-TU-002, NCT06647498: A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug, LY3372993, Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA), GHR Foundation, Private Donors
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Active, not recruiting
2/3
197
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
04/28
07/28
DIAN-TU, NCT05552157: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

Recruiting
2/3
280
Europe, Canada, US, RoW
Remternetug (SC), Matching Placebo (Remternetug)
Washington University School of Medicine, Alzheimer's Association, Eli Lilly and Company, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
03/34
08/34
Chewning, Joseph
NCT05569512: Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Terminated
1
1
US
Uproleselan, Fludarabine, Fludara, Clofarabine, Clolar, Busulfan, Busulfex, Myleran
Malika Kapadia, GlycoMimetics Incorporated
Acute Myeloid Leukemia, Pediatric Cancer
10/23
12/23
Beck, Adam W
NCT05004051: ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

Recruiting
N/A
200
Canada, US
ViTAA Analysis
ViTAA Medical Solutions
Abdominal Aortic Aneurysms
12/26
12/26
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
TAMBE, NCT05442489: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms

Approved for marketing
N/A
US
GORE Excluder Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aneurysm
 
 
NCT04875429: Zenith® Fenestrated+ Clinical Study

Recruiting
N/A
102
US
Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2
Cook Research Incorporated
Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
06/26
04/31
NCT02043691: Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies

Recruiting
N/A
300
US
Cook Custom Aortic Endograft, Zenith t-Branch Endovascular Graft, Surgeon-Modified Endograft
University of Alabama at Birmingham, Cook Group Incorporated
Juxtarenal Aortic Aneurysm, Suprarenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Penetrating Aortic Ulcer
10/27
10/27
TAMBE, NCT03728985: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms

Active, not recruiting
N/A
102
Europe, US
GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, TAMBE
W.L.Gore & Associates
Thoracoabdominal Aortic Aneurysm
01/23
09/26
Rizk, Dana
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD

Terminated
3
270
Europe, Japan, US, RoW
Bardoxolone methyl, RTA 402
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
08/23
08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
12/26
12/26
REBOOT, NCT03949855: Belimumab With Rituximab for Primary Membranous Nephropathy

Recruiting
2
58
Canada, US
Belimumab, Benlysta®, Placebo for Belimumab, Belimumab placebo, Rituximab, Rituxan®
National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), GlaxoSmithKline, PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.
Membranous Nephropathy, Nephrotic Syndrome
03/29
03/30
ASSIST, NCT05834738: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Recruiting
2
52
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
10/25
08/26
Motl, Robert W
TEAAMS, NCT05516537: Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.

Recruiting
N/A
100
US
Guidelines for Exercise in Multiple Sclerosis (GEMS), FLEX Stretching and Toning Program
University of Illinois at Chicago, University of Alabama at Birmingham, Bristol-Myers Squibb
Multiple Sclerosis
08/25
08/26
Page, David
CA209-8H3, NCT03650894: Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Active, not recruiting
2
30
US
Nivolumab, Opdivo, Ipilimumab, Yervoy, Bicalutamide, Casodex
Providence Health & Services, Bristol-Myers Squibb, Memorial Sloan Kettering Cancer Center
Breast Neoplasm Female, Breast Cancer, Breast Carcinoma, Breast Tumor
01/25
01/26
NCT03546686: Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer

Recruiting
2
80
US
Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab
University of Texas Southwestern Medical Center, Susan G. Komen Breast Cancer Foundation, Bristol-Myers Squibb, Boston Scientific Corporation, American Society of Clinical Oncology
Breast Cancer
06/26
06/28
NeoIRX, NCT04373031: Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Active, not recruiting
2
12
US
Pembrolizumab, KEYTRUDA, IRX 2
Providence Health & Services, Merck Sharp & Dohme LLC, Brooklyn ImmunoTherapeutics, LLC
Breast Cancer, Breast Neoplasms
07/23
06/25
neoHIP, NCT03747120: Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

Active, not recruiting
2
138
US
Paclitaxel, Taxol, Trastuzumab, Herceptin, Pertuzumab, Perjeta, Pembrolizumab, Keytruda
University of Texas Southwestern Medical Center, Merck Sharp & Dohme LLC, Breast Cancer Research Foundation
HER2-positive Breast Cancer, Breast Cancer
11/24
12/29
NCT06353997: Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Recruiting
2
12
US
Pembrolizumab, KEYTRUDA, INBRX-106
Providence Health & Services, Inhibrx Biosciences, Inc
Triple Negative Breast Cancer
06/27
06/29
2019-101826, NCT04896320: Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Withdrawn
1/2
40
US
Tucatinib
Providence Health & Services, Seagen Inc.
Breast Cancer Stage IV
06/23
06/23
NCT02734290: Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Active, not recruiting
1/2
29
US
Pembrolizumab, Keytruda, Paclitaxel, Taxol, Capecitabine, Xeloda
Providence Health & Services, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
08/19
12/25
NCT02950259: Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)

Active, not recruiting
1
16
US
Cyclophosphamide, Cytoxan, Indomethacin, Indocin, Omeprazole, Prilosec, Multivitamin, Vitamin
Providence Health & Services, Brooklyn ImmunoTherapeutics, LLC
Breast Neoplasm, Breast Neoplasm, Male, Triple Negative Breast Cancer
05/19
12/24
NCT04879849: A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers

Completed
1
34
US
Pembrolizumab, TAK-676, Image-guided radiation therapy
Takeda
Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
04/24
04/24
SCS T2P, NCT05659836: Spinal Cord Stimulation Trial to Permanent Prediction

Completed
N/A
28
US
Abbott SCS Systems
Abbott Medical Devices
Chronic Pain
06/23
06/23
Weise, Katherine
NCT05285553: MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms

Recruiting
N/A
900
US
MiSight 1 Day, Proclear 1 day
Coopervision, Inc.
Myopia
06/27
06/27
Subramaniam, Akila
EXPAND, NCT06808880: EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders

Recruiting
N/A
4000
US
Single-gene Noninvasive Prenatal Testing (sgNIPT)
Natera, Inc.
Single Gene NIPT
11/25
02/26
McElderry, Tom
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation

Recruiting
N/A
520
Europe, Canada, US, RoW
FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone
Boston Scientific Corporation
Persistent Atrial Fibrillation
12/25
12/27
NCT03643224: DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation

Completed
N/A
376
Europe, Canada, US, RoW
Radiofrequency Ablation
Medtronic Cardiac Rhythm and Heart Failure
Persistent Atrial Fibrillation, Atrial Fibrillation
10/24
10/24
Biggio, Joseph
KITCHEN, NCT04301518: Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs

Active, not recruiting
N/A
6500
US
Multimodal intervention strategy
Sera Prognostics, Inc., High Risk Pregnancy Center, Las Vegas, Nevada
Preterm Labor, Preterm Birth
12/24
12/26
NCT01429389: Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Recruiting
N/A
2000
Canada, US
Sequenom, Inc.
Down Syndrome, Fetal Aneuploidy
12/25
03/26
Tallaj, Jose
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
Stringer-Reasor, Erica
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects

Recruiting
3
750
Europe, US
Placebo, GLSI-100
Greenwich LifeSciences, Inc.
Breast Cancer
12/26
12/26
TBCRC049, NCT03501979: Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Active, not recruiting
2
17
US
Tucatinib, ONT-380, Trastuzumab, Capecitabine
University of Alabama at Birmingham, Translational Breast Cancer Research Consortium, Johns Hopkins University, Seagen Inc., University of Michigan, Georgetown University, University of California, San Francisco, University of Chicago, Indiana University, University of Washington, University of Texas
Metastatic Breast Cancer, Leptomeningeal Disease
07/21
07/24
AVIATOR, NCT03414658: The Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Hourglass Mar 2019 - Dec 2019 : From trial for cancer (unspecified)
Active, not recruiting
2
100
US
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Adrienne G. Waks, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University
Breast Cancer
05/23
05/25
HER2CLIMB-04, NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Active, not recruiting
2
70
US
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab deruxtecan, T-DXd, Enhertu, DS-8201
Seagen Inc.
HER2 Positive Breast Cancer
07/24
10/25
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
NCT02520063: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Hourglass Jan 2017 - Dec 2017 : From P1b/2 trial in combination with Femara and TRC105 for breast cancer
Checkmark Initiation of dosing in P1b/2 trial in combination with Femara and TRC105 in breast cancer
Feb 2016 - Feb 2016: Initiation of dosing in P1b/2 trial in combination with Femara and TRC105 in breast cancer
Active, not recruiting
1/2
15
US
Letrozole, Femara, Everolimus, Afinitor, TRC105
University of Alabama at Birmingham, Novartis Pharmaceuticals, Tracon Pharmaceuticals Inc.
Breast Cancer
12/25
12/26
SOLARA, NCT04711824: Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

Recruiting
1/2
41
US
Olaparib, Lynparza, Stereotactic Radiosurgery, SRS, Durvalumab, Imfinzi, Physicians Choice systemic chemotherapy, Paclitaxel, Nab-paclitaxel, Eribulin, Carboplatin, Cisplatin, Capecitabine, Gemcitabine
Colette Shen, AstraZeneca, University of North Carolina, Chapel Hill
Breast Cancer, Brain Metastases, Adult
11/25
11/26
KEYNOTE 721, NCT03310957 / 2017-002289-35: Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Completed
1/2
186
Europe, US, RoW
ladiratuzumab vedotin, LV, SGN-LIV1A, Pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
09/24
09/24
TBCRC 050, NCT03368729: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Active, not recruiting
1/2
46
US
Niraparib, formerly MK-4827, Trastuzumab
University of Alabama at Birmingham, Translational Breast Cancer Research Consortium, Tesaro, Inc., Susan G. Komen Breast Cancer Foundation, Breast Cancer Research Foundation of Alabama, The V Foundation
Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
11/26
12/26
NCT05134922: Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Available
N/A
US
Gedatolisib
Celcuity, Inc.
Breast Neoplasm Malignant Female
 
 
SENSE, NCT04932031: Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

Terminated
N/A
123
US
Sapere Bio, National Institute on Aging (NIA), University of North Carolina, University of Alabama at Birmingham
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
11/23
11/23
Ingram, Stacey A
WISDOM, NCT02620852: Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Recruiting
N/A
100000
US
Complete a health questionnaire, Provide a saliva sample for genetic testing, Screening advice based on a comprehensive risk assessment, Screening advice based on a basic risk assessment
University of California, San Francisco, Patient-Centered Outcomes Research Institute, Robert Wood Johnson Foundation, Color Genomics, Inc., Salesforce, National Cancer Institute (NCI), Safeway Foundation, United States Department of Defense
Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
09/25
09/25
Seay, Toni
OR-ARI-EAP-NPC, NCT04316637: Early Access Program With Arimoclomol in US Patients With NPC

Available
N/A
US
Arimoclomol
ZevraDenmark
Niemann-Pick Disease, Type C
 
 
Richardson, Joseph
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
Copper, Rachel
NCT01429389: Specimen Collection from Pregnant Women At Increased Risk for Fetal Aneuploidy

Recruiting
N/A
2000
Canada, US
Sequenom, Inc.
Down Syndrome, Fetal Aneuploidy
12/25
03/26
Porrett, Paige
NCT05340426: Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

Withdrawn
1
20
US
UKidney, Porcine Kidney, Xenotransplant
University of Alabama at Birmingham, United Therapeutics, Lung Biotechnology PBC
Kidney Failure, Chronic
06/28
06/29
Zweidler-McKay, Patrick
CADENZA, NCT03386513 / 2018-003210-40: Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Hourglass Jan 2024 - Dec 2024 : Top-line data from cohort 6 for 1L BPCDN
Active, not recruiting
1/2
179
Europe, US
IMGN632
AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
09/23
12/26
IMGN632-0802, NCT04086264: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Active, not recruiting
1/2
218
Europe, US
Azacitidine, Vidaza, Decitabine, IMGN632, CD123-targeted ADC, Venetoclax, Venclexta, Venclyxto
AbbVie, Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/26
04/26
Saxon, Nancy
NCT03973281: EASE: The Materna Prep Pivotal Study

Recruiting
N/A
450
US
Materna Prep Device, Standard of Care (SOC)
Materna Medical, University of Michigan
Vaginal Delivery, Pelvic Organ Prolapse
04/24
12/24
John, Rebecca St
NCT05004051: ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA

Recruiting
N/A
200
Canada, US
ViTAA Analysis
ViTAA Medical Solutions
Abdominal Aortic Aneurysms
12/26
12/26
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
NCT02043691: Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies

Recruiting
N/A
300
US
Cook Custom Aortic Endograft, Zenith t-Branch Endovascular Graft, Surgeon-Modified Endograft
University of Alabama at Birmingham, Cook Group Incorporated
Juxtarenal Aortic Aneurysm, Suprarenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, Penetrating Aortic Ulcer
10/27
10/27
Wilbanks, Anna
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
BDTX-1535-101, NCT05256290: Phase 1/2 Study of BDTX-1535 in Patients with Glioblastoma or Non-Small Cell Lung Cancer with EGFR Mutations

Recruiting
1/2
200
US
BDTX-1535 monotherapy
Black Diamond Therapeutics, Inc.
Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, NSCLC, Advanced Lung Carcinoma, Epidermal Growth Factor Receptor C797S, Epidermal Growth Factor Receptor G719X, EGF-R Positive Non-Small Cell Lung Cancer, EGFR-TKI Resistant Mutation
07/25
06/26
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer

Checkmark Presentation of OVATION 2 data in advanced ovarian cancer
Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer
Active, not recruiting
1/2
130
Canada, US
IMNN-001, Carboplatin, Paclitaxel
Imunon
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
07/24
11/25
Vines, Jane
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
NCT05798117: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus

Recruiting
1/2
24
Europe, US, RoW
YTB323
Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Lupus Nephritis
10/26
10/26
DTU-STEMI, NCT03947619: Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: the STEMI-DTU Trial

Active, not recruiting
N/A
527
Europe, Canada, US
Impella CP® placement prior to reperfusion with Primary PCI
Abiomed Inc.
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
09/24
10/30
Cole, Tonya
NCT04637009: A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Terminated
1
20
Canada, US
TAS1553
Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
02/23
02/23
Jamy, Omer H
ASC2ESCALATE, NCT05384587: Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

Active, not recruiting
2
196
US
asciminib, ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
09/25
10/27
HQP1351CU101, NCT04260022: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

Recruiting
1
62
US
Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab, Blincyto
Ascentage Pharma Group Inc.
Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
01/24
01/24
Clark, Stephanie
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT04987294: Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease

Terminated
2a
19
US
ALLN-346, Engineered urate oxidase, Placebo, Matching placebo capsule
Allena Pharmaceuticals
Hyperuricemia, Gout, Chronic Kidney Diseases
09/22
09/22
Spitler, Clay A
RFNA, NCT05668117: RFN-Advanced Retrograde Femoral Nailing System

Completed
N/A
53
US
Depuy Synthes Advanced Retrograde femoral nail
University of Alabama at Birmingham, DePuy Synthes
Femur Fracture
07/22
04/23
NCT04906642: Clinical Assessment of Next Science Solution on Gustilo and Anderson Type II and IIIA or IIIB Tibial Fractures

Terminated
N/A
17
US
Next Science, Standard of Care
Next Science TM, Piedmont Healthcare, Hughston Clinic
Surgical Wound Infection
07/23
09/23
Elkhanany, Ahmed
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
ImmunoADAPT, NCT03573648: Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

Active, not recruiting
2
33
US
Avelumab, Bavencio, Endocrine therapy, Hormone therapy, Palbociclib, Ibrance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Pfizer, Allegheny Health Network, National Institutes of Health (NIH)
Breast Cancer
03/25
12/25
InCITe, NCT03971409: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Recruiting
2
150
US
Anti-OX40 Antibody PF-04518600, PF-04518600, Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Binimetinib, ARRY-162, ARRY-438162, MEK162, Utomilumab, PF 05082566, PF 5082566, PF-05082566, PF-2566, Liposomal Doxorubicin, Caelyx, Lipodox, Sacituzumab Govitecan, Trodelvy, Sacituzumab Govitecan-hziy
Hope Rugo, MD, Translational Breast Cancer Research Consortium, Hoosier Cancer Research Network, Array BioPharma, Pfizer, Breast Cancer Research Foundation, Johns Hopkins University, Gilead Sciences
Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
06/25
06/25
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
04/25
09/25
Eudailey, Kyle
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
PERSEVERE, NCT05174767: - a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection

Active, not recruiting
N/A
115
US
AMDS
Artivion Inc., Syneos Health
Acute Aortic Dissection
12/23
12/29
EXTEND, NCT05639400: Thoraflex Hybrid and Relay Extension Post-Approval Study

Recruiting
N/A
200
Europe, US
Thoraflex Hybrid, RelayPro NBS
Vascutek Ltd., Bolton Medical
Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection
12/35
12/36
Dean, Joy
OR-ARI-EAP-NPC, NCT04316637: Early Access Program With Arimoclomol in US Patients With NPC

Available
N/A
US
Arimoclomol
ZevraDenmark
Niemann-Pick Disease, Type C
 
 
Bottomlee, Amy
ASSIST, NCT05834738: Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Recruiting
2
52
Europe, US, RoW
Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo
Chinook Therapeutics, Inc.
IgA Nephropathy, Immunoglobulin A Nephropathy
10/25
08/26
McManus, Leigh A
NCT05340426: Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

Withdrawn
1
20
US
UKidney, Porcine Kidney, Xenotransplant
University of Alabama at Birmingham, United Therapeutics, Lung Biotechnology PBC
Kidney Failure, Chronic
06/28
06/29
OLP-II, NCT05940857: US National OCS Liver Perfusion (OLP) Registry

Recruiting
N/A
100000
US
OCS Liver
TransMedics
Liver Transplant
10/31
10/31
Conway, Laronica
ARTIA-Cervix, NCT05197881: Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

Recruiting
N/A
125
US
Varian Ethos Adaptive Radiation Therapy
Varian, a Siemens Healthineers Company
Cervical Cancer by FIGO Stage 2018
05/26
05/28
Kaleekal, Thomas
TEAMMATE, NCT05033548: Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient

Terminated
N/A
246
US
CareDx
Transplant
02/23
07/23
ALAMO, NCT05050955: AlloSure Lung Assessment and Metagenomics Outcomes Study

Recruiting
N/A
500
Canada, US
CareDx
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
12/28
12/28
Harris, Shamika
TEAMMATE, NCT05033548: Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient

Terminated
N/A
246
US
CareDx
Transplant
02/23
07/23
ALAMO, NCT05050955: AlloSure Lung Assessment and Metagenomics Outcomes Study

Recruiting
N/A
500
Canada, US
CareDx
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
12/28
12/28
Liptrap, Elizabeth
FASTEST, NCT03496883: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Recruiting
3
860
Europe, Canada, Japan, US
Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo
Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)
Intracerebral Hemorrhage
01/28
01/28
 

Download Options